Advertisement

Bijblijven

, 20:25 | Cite as

De trombolytische behandeling van het acute herseninfarctalteplase transient ischemic attack (TIA) herseninfarct neurologische uitvalsverschijnselen

  • G.J.R. Luijckx
  • J. Schuling
Artikelen

Abstract

De recente registratie van alteplase voor de fibrinolytische behandeling van het acute herseninfarct en andere ontwikkelingen vormen de aanleiding om de stand van zaken met betrekking tot deze behandeling op een rij te zetten. Voor sommigen is deze toepassing nog steeds controversieel, anderen daarentegen zien bij een geprotocolleerde toepassing duidelijke voordelen van het middel.

Literatuurreferenties

  1. Lamberts H. In het huis van de huisarts. Lelystad: Meditekst, 1991.Google Scholar
  2. Meer K van de, Smith RJA. cva-patiënten in de huisartspraktijk. Huisarts Wet 1990;33:141-4.Google Scholar
  3. Herman B, Leyten AC, Luijk JH van, Frenken CW, Coul AAW op de, Schulte BP. Epidemiology of stroke in Tilburg, the Netherlands. Stroke 1982;13:629-34.PubMedGoogle Scholar
  4. Schuling J. Stroke patients in general practice [academisch proefschrift]. Groningen:Styx publications, 1993.Google Scholar
  5. Schuling J. Het cerebrovasculair accident: beloop en handelen van huisartsen. Hartbulletin 1994;25:222-8.Google Scholar
  6. Langhorne P, Williams BO, Gilchrist W. Do stroke units save lives? Lancet 1993;342:395-8.CrossRefPubMedGoogle Scholar
  7. Algra A, Gijn J van. Aspirin at any dose above 30 mg offers only modest protection after cerebral ischaemia. J Neurol Neurosurg Psychiatry 1996;60:197-9.CrossRefPubMedGoogle Scholar
  8. Hoffman JR. Tissue plasminogen activator for acute ischemic stroke: is the CAEP postion statement too negative? Thrombolytic therapy for acute ischemic stroke. cjem jcmu 2001;3:183-5.Google Scholar
  9. Lenzer J. Alteplase for stroke: money and optimistic claims buttress the ‘brain attack’ campaign. bmj 2002;324:723-6.CrossRefPubMedGoogle Scholar
  10. Warlow C. Who pays the guideline writers ? bmj 2002;324:726-7.Google Scholar
  11. Saver JL, Kidwell CS, Starkmans S. Thrombolysis in stroke: it works! bmj 2002;324:727-9.Google Scholar
  12. Kappelle LJ, Frijns CJM. Behandeling van patiënten met een tia of een herseninfarct. Ned Tijdschr Geneeskd 2002;146:1678-81.PubMedGoogle Scholar
  13. Wiersma TJ, Assendelft WJJ, Meijer LJ, Verhoeven S. Ingezonden reactie op ‘Behandeling van patiënten met een tia of een herseninfarct’. Ned Tijdschr Geneeskd 2002;46:2384-5.Google Scholar
  14. Vogels OJM, Mauser HM. Ingezonden reactie op ‘Behandeling van patiënten met een tia of een herseninfarct’. Ned Tijdschr Geneeskd 2002;46:2385-6.Google Scholar
  15. Albers GW, Amerenco P, Easton JD, Sacco RL, Teal P. Antithrombotic and thrombolytic therapy for ischemic stroke. Chest 2001;119:300S-320S.CrossRefPubMedGoogle Scholar
  16. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995;333:1581-7.Google Scholar
  17. Hacke W, Kaste M, Fieschi C, Toni D, Lesaffre E, Kummer R von, et al. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ecass). jama 1995;274:1017-25.CrossRefPubMedGoogle Scholar
  18. Hacke W, Kaste M, Fieschi C, Kummer R von, Davalos R, Meier D, et al. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ecass II). Second European Australian Acute Stroke Study Investigators. Lancet 1998;352:1245-51.CrossRefPubMedGoogle Scholar
  19. Clark WM, Wissman S, Albers GW, Jhamandas JH, Madden KP, Hamilton S. Recombinant tissue type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The atlantis Study: a randomized controlled trial. Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke. jama 1999;282:2019 26.CrossRefPubMedGoogle Scholar
  20. Swieten JC van, Koudstaal PJ, Visser MC, Schouten HJ, Gijn J van. Interobserver agreement for the assessment of handicap in stroke patients. Stroke 1988;19:604-7.PubMedGoogle Scholar
  21. Bamford JM, Sandercock PA, Warlow CP, Slattery J. Interobserver agreement for the assessment of handicap in stroke patients [letter]. Stroke 1989;20:828.PubMedGoogle Scholar
  22. Kwiatkowski TG, Libman RB, Frankel M, Tilley BC, Morgenstern LB, Lu M, et al. Effects of tissue plasminogen activator for acute ischemic stroke at one year. National Institute of Neurological Disorders and Stroke Recombinant Tissue Plasminogen Activator Stroke Study Group. N Engl J Med 1999;340:1781-7.CrossRefPubMedGoogle Scholar
  23. Multicenter Acute Stroke Trial Italy (MAST-I) Group. Randomised controlled trial of streptokinase, aspirin, and combination of both in treatment of acute ischemic stroke. Lancet 1995;346:1509-14.Google Scholar
  24. The Multicenter Acute Stroke Trial-Europe Study Group. Thrombolytic therapy with streptokinase in acute ischemic stroke. N Engl J Med 1996;335:145-50.Google Scholar
  25. Donnan GA, Davis SM, Chambers BR, Gates PC, Hankey GJ, McNeil JJ, et al. Streptokinase for acute ischemic stroke with relationship to time of administration. The Australian Streptokinase (ask) Trial Study Group. jama 1996;276:961-6.CrossRefPubMedGoogle Scholar
  26. Morris AD, Ritchie C, Grosset DG, Adams FG, Lees KR. A pilot study of streptokinase for acute cerebral infarction. Q J Med 1995;88:727-31.Google Scholar
  27. Wardlaw JM, Zoppo G del, Yamaguchi T, Berge E. Thrombolysis for acute ischemic stroke. Oxford: The Cochrane Library. Update Software, 2003: issue 3.Google Scholar
  28. Furlan AF, Higashida F, Wechsler L, Gent M, Rowley H, Kase C, et al. Intra-arterial prourokinase for acute ischemic stroke. The proact II study:a randomized controlled trial. jama 1999;282:2003-11.CrossRefPubMedGoogle Scholar
  29. Zoppo GJ del, Higashida RT, Furlan AJ, Pessin MS, Rowley HA, Gent M. proact: a phase II randomized trial of recombinant pro-urokinase by direct arterial delivery in acute middle cerebral artery stroke. Stroke 1998;29:4-11.PubMedGoogle Scholar
  30. Albers GW, Bates VE, Clark WM, Bell R, Verro P, Hamilton SA. Intravenous tissue-type plasminogen activator for treatment of acute stroke: the standard treatment with alteplase to reveil stroke (stars) study. jama 2000;283:1189-91 (Comment).CrossRefGoogle Scholar
  31. Grond M, Stenzel C, Schmulling S, Rudolf J, Neveling M, Lechleuth A, et al. Early intravenous thrombolysis for acute ischemic stroke in a community-based approach. Stroke 1998;29:1544-49.PubMedGoogle Scholar
  32. Grotta JC, Burgin WS, El-Mitwalli A, Long M, Campbell M, Morgenstern LB, et al. Intravenous tissue-type plasmogen activator therapy for ischemic stroke: Houston experience 1996 to 2000. Arch Neurol. 2001;58:2009-13.CrossRefPubMedGoogle Scholar
  33. Katzan IL, Furlan AJ, Lloyd LE, Frank JI, Harper DL, Hinchey JA, et al. Use of tissue-type plasminogen activator for acute ischemic stroke: the Cleveland area experience. jama 2000;283:1151-8.CrossRefPubMedGoogle Scholar
  34. Lindsberg PJ, Kaste M. Thrombolysis for acute stroke. Curr Opin Neurol 2003;16:73-80.CrossRefPubMedGoogle Scholar
  35. Patel SC, Levine SR, Tilley BC, Grotta JC, Lu M, Frankel M, et al. Lack of clinical significance of early ischemic changes on computed tomography in acute stroke. jama 2001;286:2830-8.CrossRefPubMedGoogle Scholar
  36. Demchuk AM, Tanne D, Hill MD, Kasner SE, Hanson S, Grond M, et al. Predictors of good outcome after intravenous tPA for acute ischemic stroke. Neurology 2001;57:474-80.PubMedGoogle Scholar

Copyright information

© Bohn Stafleu van Loghum 2004

Authors and Affiliations

  • G.J.R. Luijckx
    • 1
  • J. Schuling
    • 1
  1. 1.

Personalised recommendations